Navigation Links
Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence

Aromatase Inhibitors drug, Femara given after 5 years of Tamoxifen therapy is found to give protection against occurrence of Breast cancer recurrence. Breast cancer is the second leading cause of cancer// in women. Breast cancer mostly occurs in post menopausal women and various risk factors are attributed for the occurrence of breast cancer.

Treatment of breast cancer initially involves removal of the entire breast or part of the breast with the cancer lump followed by Radiation therapy and Chemotherapy. Cytotoxic drugs are given as chemotherapy for patients with breast cancer; usually 6 cycles of chemotherapeutic drugs are given such as Cyclophosphamide, 5 flurouracil, adiramycin. After these procedures 5 years of Tamoxifen therapy is recommended for post menopausal women. Tamoxifen therapy is recommended only for 5 years as studies in which tamoxifen given for more than 5 years shows no difference. Tamoxifen acts as an anti-estrogen by which it competitively inhibits the estrogens produced by the body, as estrogen is used up by the cancer cell for its growth and production. Metastasis and recurrence occurs in some cancer patients, though the chance of metastasis is very less as only 1 in 10000 cells has the capacity to reach the blood stream and cause cancer in a new organ.

Recurrence mostly occurs due to pitfalls or not properly taking therapy or tablets, even tamoxifen resistance developed by the patient may also lead to recurrence. Recurrence may occur at the same initial cancer site called as loco-regional or in a new site.

The new study using Femara Aromatase Inhibitors after 5 years of Tamoxifen therapy as found to give protection against occurrence of recurrence. Aromatase inhibitors lower the levels of estrogen in the body by acting on the Aromatase enzyme involved in making estrogen. The study was conducted in 5000 postmenopausal women who have finished their 5 years tamoxifen therapy and they were given femara for an other
'"/>




Page: 1 2

Related medicine news :

1. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
2. Early Switch to an Aromatase Inhibitor Increases Survival
3. LipB Protein Inhibitors Help To Fight Against TB
4. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
5. ACE Inhibitors For Vascular Disease Patients
6. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
7. Femara: The Wonder Drug to Prevent Relapse of Breast Cancer.
8. Thyroid hormone treatment hastens recovery after cardiac surgery
9. Morning after pill effective up to five days after having unprotected sex
10. Liver donors can thrive after transplant
11. Recouping blood flow after a stroke
Post Your Comments:
(Date:9/2/2015)... ... September 02, 2015 , ... ... large stream of mixed documents that include EOBs, payments, and payment related documents. ... the data needed to reconcile their billing, with one efficient process and interface,“ ...
(Date:9/2/2015)... Pittsburgh, PA (PRWEB) , ... September 02, 2015 ... ... the Health Sciences clinical and academic partnership has earned international recognition as a ... rare genetic disorder that can cause sudden, catastrophic internal bleeding and stroke. ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... largest and fastest-growing interim clinical staffing companies, has completed a recapitalization with ... , BPOC and Heritage Group each offer extensive expertise and ...
(Date:9/2/2015)... Kansas City, KS (PRWEB) , ... September 02, 2015 , ... ... recently opened its newest office in Kansas – its Johnson County location. ... backgrounds in healthcare. Mike has a registered nurse background and spent over 20 years ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be ... risk of getting ovarian cancer in her lifetime is approximately 1 in 75. This ... ovarian cancer, and 14,000 will die. , There is no test to detect ...
Breaking Medicine News(10 mins):Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3
... , , WASHINGTON, July 24 ... today in support of the minimum wage increase from $6.55 an hour ... minimum wage increase is an important step in recovering our economy, rebuilding ... it is only one of three prongs necessary to create a real ...
... common, but labeling is not required, report states , ... "enhance" uncooked meat and poultry can pose serious health ... Many fresh meat and poultry products are injected with ... not required to be listed on food labels, according ...
... , , CLEVELAND, July 24 /PRNewswire/ ... access for the uninsured and underinsured to a wide range of health ... 25 and 26, at the W.O. Walker Center, 10524 Euclid Ave. The ... provide 1100 medical, 300 vision and 200 dental patient visits. Appointments ...
... , CHICAGO, July 24 ... in designing and manufacturing portable rechargeable systems, today ... single-output power supplies. The new 350-watt series, designed ... delivers an industry-leading converter efficiency of up to ...
... WESTBROOK, Maine, July 24 IDEXX Laboratories, Inc. (Nasdaq: ... second quarter of 2009 were $265.7 million compared to $280.6 ... as defined below, was 5%. Earnings per diluted share ("EPS") ... to $0.63 for the same period in the prior year. ...
... ... Texans find affordable, direct access to medical lab testing through Any Lab Test Now®. , ... Plano, TX (PRWEB) July 24, 2009 -- This ... company has found its niche. Opened December 2008, Any Lab Test Now® in ...
Cached Medicine News:Health News:Fresh-Meat Additives May Be Dangerous for Kidney Patients 2Health News:U.S. Senator Sherrod Brown to Lend Support at MedWorks' Free Medical Clinic This Weekend 2Health News:Convection Cooled 350-Watt Open Frame Power Supply Meets Medical and Industrial Safety Standards 2Health News:IDEXX Laboratories Announces Second Quarter Results 2Health News:IDEXX Laboratories Announces Second Quarter Results 3Health News:IDEXX Laboratories Announces Second Quarter Results 4Health News:IDEXX Laboratories Announces Second Quarter Results 5Health News:IDEXX Laboratories Announces Second Quarter Results 6Health News:IDEXX Laboratories Announces Second Quarter Results 7Health News:IDEXX Laboratories Announces Second Quarter Results 8Health News:IDEXX Laboratories Announces Second Quarter Results 9Health News:IDEXX Laboratories Announces Second Quarter Results 10Health News:IDEXX Laboratories Announces Second Quarter Results 11Health News:IDEXX Laboratories Announces Second Quarter Results 12Health News:IDEXX Laboratories Announces Second Quarter Results 13Health News:IDEXX Laboratories Announces Second Quarter Results 14Health News:IDEXX Laboratories Announces Second Quarter Results 15Health News:IDEXX Laboratories Announces Second Quarter Results 16Health News:IDEXX Laboratories Announces Second Quarter Results 17Health News:IDEXX Laboratories Announces Second Quarter Results 18Health News:IDEXX Laboratories Announces Second Quarter Results 19Health News:IDEXX Laboratories Announces Second Quarter Results 20Health News:IDEXX Laboratories Announces Second Quarter Results 21Health News:IDEXX Laboratories Announces Second Quarter Results 22Health News:Cost-Conscious Texans Find Relief with Direct Access Lab Testing 2
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015  Seeger ... knee implant bellwether trial will commence October 13, 2015. ... 1995 using the 510K fast-track approval program, Zimmer NexGen ... The program only requires that companies provide evidence that ... approved product in order to gain permissions. ...
(Date:9/2/2015)... 2, 2015 Research and Markets ( ... "Medical Device Studies: Clinical Evidence (London, UK ... offering. This course has been ... gathering clinical evidence required for medical devices and ... all medical devices and the emphasis on high ...
(Date:9/2/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... Officer of Neurocrine Biosciences, will be presenting at the ... City . The live presentation takes ... PT).  The presentation will be webcast and may be ... Listeners are encouraged to visit the ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... 2 HART Health, a national manufacturer and distributor ... service division of Synergy Logistics, a Seattle-based first aid ... new franchise system. Synergy Logistics, Inc. had ... delivery service to mid-sized Seattle businesses since the early ...
... Results from studies related to ... lead developmental product candidate, fidaxomicin, will ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ... Exhibition Center in Boston on September 12-15, 2010. ...
Cached Medicine Technology:First Aid Supplier HART Health Acquires Competitor and Continues Expansion 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: